Xianju Pharmaceutical released its 2026 interim report. Total operating revenue was 1.959 billion yuan, up 4.78% year-on-year, but net profit attributable to the parent was 245 million yuan, down 20.67% year-on-year. Net cash inflow from operating activities was 360 million yuan, an increase of 360 million yuan year-on-year. The asset-liability ratio was 15.23%, down 1.50 percentage points from the same period last year. Gross margin was 62.15%, down 1.01 percentage points from the same period last year. ROE was 4.10%, down 1.03 percentage points from the same period last year. Diluted earnings per share were 0.25 yuan, down 20.67% year-on-year.
Zhejiang Xianju Pharmaceutical Co LtdNet profit fell 20.67% year-on-year despite revenue growth.
